Inhibitors of CDK, termed cyclin-dependent kinase inhibitors (CKIs), regulate CDK activity and decreased expression of these regulatory proteins is frequently observed in many cancers, with p16, which is encoded by the gene CDKN2A, being the most well characterized CKI. This evidence concerns the gene CDKN2A and cancer.